enGene Therapeutics Inc. (ENGN) stock forecast and price target
Price $2.41 · data as of November 13, 2026
12-month price target
Average target$4.29
Upside / downside+77.8%
Analysts7
ConsensusBuy
Low $2.00Average $4.29High $6.00
Gold marker: average target · white marker: today’s price ($2.41)
Analyst ratings
Strong buy 2Buy 4Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Next fiscal year ends October 31, 2027 | $-1.59 | +12.4% | $5M |
| Quarter after ends January 31, 2027 | $-0.38 | +14.4% | $0 |
Consensus of the analysts covering enGene Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 6 lowered.
Frequently asked questions
What is the enGene Therapeutics stock price target?
The average 12-month target from 7 analysts is $4.29, 77.8% above the current price of $2.41 Targets range from $2.00 to $6.00.
Is enGene Therapeutics a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 4 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.